Alpine Woods Capital Investors LLC Has $1.45 Million Position in Intra-Cellular Therapies Inc. (ITCI)
Alpine Woods Capital Investors LLC boosted its position in Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 24.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 91,544 shares of the biopharmaceutical company’s stock after acquiring an additional 18,000 shares during the quarter. Alpine Woods Capital Investors LLC owned 0.17% of Intra-Cellular Therapies worth $1,445,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd purchased a new position in Intra-Cellular Therapies in the third quarter valued at approximately $244,000. Columbus Circle Investors purchased a new position in Intra-Cellular Therapies in the third quarter valued at approximately $2,482,000. SG Americas Securities LLC increased its stake in Intra-Cellular Therapies by 45.9% in the third quarter. SG Americas Securities LLC now owns 12,060 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 3,794 shares during the last quarter. Quantbot Technologies LP increased its stake in Intra-Cellular Therapies by 233.1% in the third quarter. Quantbot Technologies LP now owns 8,614 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 6,028 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Intra-Cellular Therapies in the third quarter valued at approximately $101,000. 61.10% of the stock is currently owned by hedge funds and other institutional investors.
ITCI has been the topic of several recent analyst reports. BidaskClub lowered shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Leerink Swann reiterated a “market perform” rating and issued a $12.00 price target on shares of Intra-Cellular Therapies in a research note on Tuesday, August 15th. Zacks Investment Research lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. ValuEngine lowered shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 27th. Finally, SunTrust Banks, Inc. restated a “hold” rating and set a $22.00 target price (up from $16.00) on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. Intra-Cellular Therapies presently has a consensus rating of “Buy” and an average price target of $25.00.
In related news, major shareholder Alafi Capital Co Llc purchased 258,065 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was purchased at an average cost of $15.50 per share, with a total value of $4,000,007.50. Following the completion of the acquisition, the insider now directly owns 3,953,270 shares in the company, valued at $61,275,685. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Sharon Mates sold 18,750 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $15.75, for a total value of $295,312.50. Following the sale, the chief executive officer now directly owns 1,107,457 shares of the company’s stock, valued at $17,442,447.75. The disclosure for this sale can be found here. 21.00% of the stock is owned by company insiders.
Shares of Intra-Cellular Therapies Inc. (NASDAQ ITCI) traded up $0.85 on Tuesday, hitting $16.17. 949,500 shares of the stock were exchanged, compared to its average volume of 694,189. Intra-Cellular Therapies Inc. has a twelve month low of $7.85 and a twelve month high of $22.67.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.06 million. During the same period last year, the company earned ($0.70) earnings per share. The company’s revenue for the quarter was up 675.0% on a year-over-year basis. research analysts predict that Intra-Cellular Therapies Inc. will post -2.16 EPS for the current year.
WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/21/alpine-woods-capital-investors-llc-has-1-45-million-position-in-intra-cellular-therapies-inc-itci.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).
Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.